Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN 1 phase 3 trial of LYR-210 for chronic rhinosinusitis in adults
2021-005906-83Phase 3Completed
- Sponsor
- Lyra Therapeutics, Inc.
- Start
- May 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LYR-210 in chronic rhinosinusitis (CRS) and rhinosinusitis (2 arms), sponsored by Lyra Therapeutics, Inc. Primary endpoint: Change from baseline in 7-day average composite score of 3 cardinal CRS symptoms (primary timepoint). Started May 2022; status: completed.
02
Drugs
LYR-210
03
Conditions
chronic rhinosinusitis (CRS)rhinosinusitis
Beyond the preview
Go deeper on 2021-005906-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005906-83.